Seminars in Arthritis and Rheumatism
Volume 40, Issue 2 , Pages 97-108 , October 2010

The Antiphospholipid Syndrome as a Neurological Disease

  • Yoav Arnson, MD

      Affiliations

    • Department of Medicine D, Meir Medical Center, Kfar Saba and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • ,
  • Yehuda Shoenfeld, MD

      Affiliations

    • Department of Medicine B and Center for Autoimmune Diseases, and Tel Aviv University, Sackler Faculty of Medicine, Sheba Medical Center, Tel Hashomer, Israel
    • ,
  • Eisen Alon, MD

      Affiliations

    • Department of Medicine D, Meir Medical Center, Kfar Saba and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • ,
  • Howard Amital, MD, MHA

      Affiliations

    • Department of Medicine D, Meir Medical Center, Kfar Saba and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
    • Corresponding Author InformationAddress reprint requests to: Howard Amital, MD, MHA, Head of Department of Medicine D, Meir Medical Center, Tshernichovsky 59, Kfar Saba, 95847, Israel

References 

  1. Hughes GR. The antiphospholipid syndrome: ten years on. Lancet. 1993;342:341–344
  2. Bertolaccini ML, Khamashta MA, Hughes GR. Diagnosis of antiphospholipid syndrome. Nat Clin Pract Rheumatol. 2005;1:40–46
  3. Hughes GR. The anticardiolipin syndrome. Clin Exp Rheumatol. 1985;3:285–286
  4. Lowy I. Scientific facts and their public: the history of the diagnosis of syphilis. Rev Synth. 1995;116:27–54
  5. Conley CL, Rathbun HK, Orse WI, Onibson JE. Circulating anticoagulants as a cause of hemorrhagic diathesis in man. Bull Johns Hopkins Hosp. 1948;83:288–293
  6. McIntyre JA, Wagenknecht DR, Sugi T. Phospholipid binding plasma proteins required for antiphospholipid antibody detection—an overview. Am J Reprod Immunol. 1997;37:101–110
  7. Shan H, Goldman J, Cunto G, Manuppello J, Chaiken I, Cines DB, et al. Heterogeneity of anti-phospholipid and anti-endothelial cell antibodies. J Autoimmun. 1998;11:651–660
  8. Shoenfeld Y, Twig G, Katz U, Sherer Y. Autoantibody explosion in antiphospholipid syndrome. J Autoimmun. 2008;30:74–83
  9. Wilson WA. Classification criteria for antiphospholipid syndrome. Rheum Dis Clin North Am. 2001;27:499–505v
  10. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 2006;295:1050–1057
  11. Roubey RA. Mechanisms of autoantibody-mediated thrombosis. Lupus. 1998;7(Suppl 2):S114–S119
  12. Pierangeli SS, Chen PP, Gonzalez EB. Antiphospholipid antibodies and the antiphospholipid syndrome: an update on treatment and pathogenic mechanisms. Curr Opin Hematol. 2006;13:366–375
  13. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation. 1999;99:1997–2002
  14. Khamashta MA, Harris EN, Gharavi AE, Derue G, Gil A, Vazquez JJ, et al. Immune mediated mechanism for thrombosis: antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis. 1988;47:849–854
  15. Campbell AL, Pierangeli SS, Wellhausen S, Harris EN. Comparison of the effects of anticardiolipin antibodies from patients with the antiphospholipid syndrome and with syphilis on platelet activation and aggregation. Thromb Haemost. 1995;73:529–534
  16. Vismara A, Meroni PL, Tincani A, Harris EN, Barcellini W, Brucato A, et al. Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus. Clin Exp Immunol. 1988;74:247–253
  17. Harris EN, Pierangeli SS. Functional effects of anticardiolipin antibodies. Lupus. 1996;5:372–377
  18. Marciniak E, Romond EH. Impaired catalytic function of activated protein C: a new in vitro manifestation of lupus anticoagulant. Blood. 1989;74:2426–2432
  19. Cabiedes J, Cabral AR, Alarcon-Segovia D. Clinical manifestations of the antiphospholipid syndrome in patients with systemic lupus erythematosus associate more strongly with anti-beta 2-glycoprotein-I than with antiphospholipid antibodies. J Rheumatol. 1995;22:1899–1906
  20. Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest. 1995;96:2211–2219
  21. Muller S, Dieker J, Tincani A, Meroni PL. Pathogenic anti-nucleosome antibodies. Lupus. 2008;17:431–436
  22. Meroni PL, Tincani A, Sepp N, Raschi E, Testoni C, Corsini E, et al. Endothelium and the brain in CNS lupus. Lupus. 2003;12:919–928
  23. Abbott NJ, Mendonca LL, Dolman DE. The blood-brain barrier in systemic lupus erythematosus. Lupus. 2003;12:908–915
  24. Espinosa G, Cervera R, Font J, Shoenfeld Y. Antiphospholipid syndrome: pathogenic mechanisms. Autoimmun Rev. 2003;2:86–93
  25. Trysberg E, Nylen K, Rosengren LE, Tarkowski A. Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum. 2003;48:2881–2887
  26. Chapman J, Cohen-Armon M, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies permeabilize and depolarize brain synaptoneurosomes. Lupus. 1999;8:127–133
  27. Sun KH, Liu WT, Tsai CY, Liao TS, Lin WM, Yu CL. Inhibition of astrocyte proliferation and binding to brain tissue of anticardiolipin antibodies purified from lupus serum. Ann Rheum Dis. 1992;51:707–712
  28. Ball-Rosen C, Primak-Rubinovicz H, Korczyn AD, Wang N, Farchi A, Shavit S, et al. Identification of histidine-rich glycoprotein, a potential autoantigen, in human and rat brain preparations. Ann NY Acad Sci. 2007;1109:473–483
  29. Khalili A, Cooper RC. A study of immune responses to myelin and cardiolipin in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol. 1991;85:365–372
  30. Oosting JD, Derksen RH, Hackeng TM, van VM, Preissner KT, Bouma BN, et al. In vitro studies of antiphospholipid antibodies and its cofactor, beta 2-glycoprotein I, show negligible effects on endothelial cell mediated protein C activation. Thromb Haemost. 1991;66:666–671
  31. Simantov R, LaSala JM, Lo SK, Gharavi AE, Sammaritano LR, Salmon JE, et al. Activation of cultured vascular endothelial cells by antiphospholipid antibodies. J Clin Invest. 1995;96:2211–2219
  32. Riccio A, Andreassi C, Eboli ML. Antiphospholipid antibodies bind to rat cerebellar granule cells: the role of N-methyl-D-aspartate receptors. Neurosci Lett. 1998;257:116–118
  33. Ziporen L, Polak-Charcon S, Korczyn DA, Goldberg I, Afek A, Kopolovic J, et al. Neurological dysfunction associated with antiphospholipid syndrome: histopathological brain findings of thrombotic changes in a mouse model. Clin Dev Immunol. 2004;11:67–75
  34. Smith HR, Hansen CL, Rose R, Canoso RT. Autoimmune MRL-1 pr/1pr mice are an animal model for the secondary antiphospholipid syndrome. J Rheumatol. 1990;17:911–915
  35. Katzav A, Litvinjuk Y, Pick CG, Blank M, Shoenfeld Y, Sirota P, et al. Genetic and immunological factors interact in a mouse model of CNS antiphospholipid syndrome. Behav Brain Res. 2006;169:289–293
  36. Pierangeli SS, Harris EN. Induction of phospholipid-binding antibodies in mice and rabbits by immunization with human beta 2 glycoprotein 1 or anticardiolipin antibodies alone. Clin Exp Immunol. 1993;93:269–272
  37. Blank M, Faden D, Tincani A, Kopolovic J, Goldberg I, Gilburd B, et al. Immunization with anticardiolipin cofactor (beta-2-glycoprotein I) induces experimental antiphospholipid syndrome in naive mice. J Autoimmun. 1994;7:441–455
  38. Haj-Yahia S, Sherer Y, Blank M, Kaetsu H, Smolinsky A, Shoenfeld Y. Anti-prothrombin antibodies cause thrombosis in a novel qualitative ex-vivo animal model. Lupus. 2003;12:364–369
  39. Brey RL, Escalante A. Neurological manifestations of antiphospholipid antibody syndrome. Lupus. 1998;7(Suppl 2):S67–S74
  40. Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, Hughes GR. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford). 2003;42:200–213
  41. Harris EN, Gharavi AE, Kworth-Young CG, Patel BM, Derue G, Hughes GR. Lupoid sclerosis: a possible pathogenetic role for antiphospholipid antibodies. Ann Rheum Dis. 1985;44:281–283
  42. Harris EN, Englert H, Derve G, Hughes GR, Gharavi A. Antiphospholipid antibodies in acute Guillain-Barre syndrome. Lancet. 1983;2:1361–1362
  43. Asherson RA, Mercey D, Phillips G, Sheehan N, Gharavi AE, Harris EN, et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis. 1987;46:605–611
  44. Chapman J, Shoenfeld Y. Neurological and neuroendocrine-cytokine inter-relationship in the antiphospholipid syndrome. Ann NY Acad Sci. 2002;966:415–424
  45. Levine SR, Welch KM. The spectrum of neurologic disease associated with antiphospholipid antibodies (Lupus anticoagulants and anticardiolipin antibodies). Arch Neurol. 1987;44:876–883
  46. Shoenfeld Y, Lev S, Blatt I, Blank M, Font J, von LP, et al. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol. 2004;31:1344–1348
  47. Miesbach W, Gilzinger A, Gokpinar B, Claus D, Scharrer I. Prevalence of antiphospholipid antibodies in patients with neurological symptoms. Clin Neurol Neurosurg. 2006;108:135–142
  48. Krause I, Leibovici L, Blank M, Shoenfeld Y. Clusters of disease manifestations in patients with antiphospholipid syndrome demonstrated by factor analysis. Lupus. 2007;16(3):176–180
  49. Shah NM, Khamashta MA, Atsumi T, Hughes GR. Outcome of patients with anticardiolipin antibodies: a 10 year follow-up of 52 patients. Lupus. 1998;7:3–6
  50. Montalban J, Rio J, Khamastha M, Davalos A, Codina M, Swana GT, et al. Value of immunologic testing in stroke patients (A prospective multicenter study). Stroke. 1994;25:2412–2415
  51. Hughes GR. Migraine, memory loss, and “multiple sclerosis” (Neurological features of the antiphospholipid (Hughes') syndrome). Postgrad Med J. 2003;79:81–83
  52. The Antiphospholipid Antibodies in Stroke Study Group. Clinical and laboratory findings in patients with antiphospholipid antibodies and cerebral ischemia. Stroke. 1990;21:1268–1273
  53. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–1027
  54. Levine SR, Salowich-Palm L, Sawaya KL, Perry M, Spencer HJ, Winkler HJ, et al. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death (A prospective cohort study). Stroke. 1997;28:1660–1665
  55. Levine SR, Deegan MJ, Futrell N, Welch KM. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology. 1990;40:1181–1189
  56. Brey RL, Abbott RD, Curb JD, Sharp DS, Ross GW, Stallworth CL, et al. beta(2)-Glycoprotein 1-dependent anticardiolipin antibodies and risk of ischemic stroke and myocardial infarction: the Honolulu heart program. Stroke. 2001;32:1701–1706
  57. Krause I, Lev S, Fraser A, Blank M, Lorber M, Stojanovich L, et al. Close association between valvar heart disease and central nervous system manifestations in the antiphospholipid syndrome. Ann Rheum Dis. 2005;64:1490–1493
  58. Champion RH, Rook A. Livedo reticularis. Proc R Soc Med. 1960;53:961–962
  59. Schellong SM, Weissenborn K, Niedermeyer J, Wollenhaupt J, Sosada M, Ehrenheim C, et al. Classification of Sneddon's syndrome. Vasa. 1997;26:215–221
  60. Briley DP, Coull BM, Goodnight SH. Neurological disease associated with antiphospholipid antibodies. Ann Neurol. 1989;25:221–227
  61. Levine SR, Salowich-Palm L, Sawaya KL, Perry M, Spencer HJ, Winkler HJ, et al. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death (A prospective cohort study). Stroke. 1997;28:1660–1665
  62. Shoenfeld Y, Lev S, Blatt I, Blank M, Font J, von LP, et al. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol. 2004;31:1344–1348
  63. Cimaz R, Meroni PL, Shoenfeld Y. Epilepsy as part of systemic lupus erythematosus and systemic antiphospholipid syndrome (Hughes syndrome). Lupus. 2006;15:191–197
  64. Hughes GR. Migraine, memory loss, and “multiple sclerosis” (Neurological features of the antiphospholipid (Hughes') syndrome). Postgrad Med J. 2003;79:81–83
  65. Silverman IE, Restrepo L, Mathews GC. Poststroke seizures. Arch Neurol. 2002;59:195–201
  66. Eriksson K, Peltola J, Keranen T, Haapala AM, Koivikko M. High prevalence of antiphospholipid antibodies in children with epilepsy: a controlled study of 50 cases. Epilepsy Res. 2001;46:129–137
  67. Verrot D, San-Marco M, Dravet C, Genton P, Disdier P, Bolla G, et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med. 1997;103:33–37
  68. Shoenfeld Y, Lev S, Blatt I, Blank M, Font J, von LP, et al. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol. 2004;31:1344–1348
  69. Weingarten K, Filippi C, Barbut D, Zimmerman RD. The neuroimaging features of the cardiolipin antibody syndrome. Clin Imaging. 1997;21:6–12
  70. Hilker R, Thiel A, Geisen C, Rudolf J. Cerebral blood flow and glucose metabolism in multi-infarct-dementia related to primary antiphospholipid antibody syndrome. Lupus. 2000;9:311–316
  71. Chapman J, Soloveichick L, Shavit S, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies bind ATP: a putative mechanism for the pathogenesis of neuronal dysfunction. Clin Dev Immunol. 2005;12:175–180
  72. Liou HH, Wang CR, Chou HC, Arvanov VL, Chen RC, Chang YC, et al. Anticardiolipin antisera from lupus patients with seizures reduce a GABA receptor-mediated chloride current in snail neurons. Life Sci. 1994;54:1119–1125
  73. Mosek A, Yust I, Treves TA, Vardinon N, Korczyn AD, Chapman J. Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord. 2000;11:36–38
  74. Jacobson MW, Rapport LJ, Keenan PA, Coleman RD, Tietjen GE. Neuropsychological deficits associated with antiphospholipid antibodies. J Clin Exp Neuropsychol. 1999;21:251–264
  75. Mosek A, Yust I, Treves TA, Vardinon N, Korczyn AD, Chapman J. Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord. 2000;11:36–38
  76. Juby A, Davis P, Genge T, McElhaney J. Anticardiolipin antibodies in two elderly subpopulations. Lupus. 1995;4:482–485
  77. Chapman J, Rand JH, Brey RL, Levine SR, Blatt I, Khamashta MA, et al. Non-stroke neurological syndromes associated with antiphospholipid antibodies: evaluation of clinical and experimental studies. Lupus. 2003;12:514–517
  78. Denburg SD, Carbotte RM, Ginsberg JS, Denburg JA. The relationship of antiphospholipid antibodies to cognitive function in patients with systemic lupus erythematosus. J Int Neuropsychol Soc. 1997;3:377–386
  79. Asherson RA, Mercey D, Phillips G, Sheehan N, Gharavi AE, Harris EN, et al. Recurrent stroke and multi-infarct dementia in systemic lupus erythematosus: association with antiphospholipid antibodies. Ann Rheum Dis. 1987;46:605–611
  80. Caronti B, Calderaro C, Alessandri C, Conti F, Tinghino R, Pini C, et al. Serum anti-beta2-glycoprotein I antibodies from patients with antiphospholipid antibody syndrome bind central nervous system cells. J Autoimmun. 1998;11:425–429
  81. Caronti B, Pittoni V, Palladini G, Valesini G. Anti-beta 2-glycoprotein I antibodies bind to central nervous system. J Neurol Sci. 1998;156:211–219
  82. Olazarán J, López-Longo J, Cruz I, Bittini A, Carreño L. Cognitive dysfunction in systemic lupus erythematosus: prevalence and correlates. Eur Neurol. 2009;62:49–55
  83. Menon S, Jameson-Shortall E, Newman SP, Hall-Craggs MR, Chinn R, Isenberg DA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum. 1999;42:735–741
  84. Whitelaw DA, Spangenberg JJ, Rickman R, Hugo FH, Roberts M. The association between the antiphospholipid antibody syndrome and neuropsychological impairment in SLE. Lupus. 1999;8:444–448
  85. Schmidt R, uer-Grumbach P, Fazekas F, Offenbacher H, Kapeller P. Anticardiolipin antibodies in normal subjects (Neuropsychological correlates and MRI findings). Stroke. 1995;26:749–754
  86. Tektonidou MG, Varsou N, Kotoulas G, Antoniou A, Moutsopoulos HM. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med. 2006;166:2278–2284
  87. Kao CH, Lan JL, Hsieh JF, Ho YJ, ChangLai SP, Lee JK, et al. Evaluation of regional cerebral blood flow with 99mTc-HMPAO in primary antiphospholipid antibody syndrome. J Nucl Med. 1999;40:1446–1450
  88. Zandman-Goddard G, Chapman J, Shoenfeld Y. Autoantibodies involved in neuropsychiatric SLE and antiphospholipid syndrome. Semin Arthritis Rheum. 2007;36:297–315
  89. Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies (A mouse model). J Clin Invest. 1997;100:613–619
  90. Ziporen L, Polak-Charcon S, Korczyn DA, Goldberg I, Afek A, Kopolovic J, et al. Neurological dysfunction associated with antiphospholipid syndrome: histopathological brain findings of thrombotic changes in a mouse model. Clin Dev Immunol. 2004;11:67–75
  91. Katzav A, Pick CG, Korczyn AD, Oest E, Blank M, Shoenfeld Y, et al. Hyperactivity in a mouse model of the antiphospholipid syndrome. Lupus. 2001;10:496–499
  92. Shrot S, Katzav A, Korczyn AD, Litvinju Y, Hershenson R, Pick CG, et al. Behavioral and cognitive deficits occur only after prolonged exposure of mice to antiphospholipid antibodies. Lupus. 2002;11:736–743
  93. Shoenfeld Y, Nahum A, Korczyn AD, Dano M, Rabinowitz R, Beilin O, et al. Neuronal-binding antibodies from patients with antiphospholipid syndrome induce cognitive deficits following intrathecal passive transfer. Lupus. 2003;12:436–442
  94. Hughes GR. Migraine, memory loss, and “multiple sclerosis” (Neurological features of the antiphospholipid (Hughes') syndrome). Postgrad Med J. 2003;79:81–83
  95. Levine SR, Joseph R, D'Andrea G, Welch KM. Migraine and the lupus anticoagulant (Case reports and review of the literature). Cephalalgia. 1987;7:93–99
  96. Alarcon-Segovia D, Deleze M, Oria CV, Sanchez-Guerrero J, Gomez-Pacheco L, Cabiedes J, et al. Antiphospholipid antibodies and the antiphospholipid syndrome in systemic lupus erythematosus (A prospective analysis of 500 consecutive patients). Medicine (Baltimore). 1989;68:353–365
  97. Montalban J, Cervera R, Font J, Ordi J, Vianna J, Haga HJ, et al. Lack of association between anticardiolipin antibodies and migraine in systemic lupus erythematosus. Neurology. 1992;42:681–682
  98. Verrotti A, Cieri F, Pelliccia P, Morgese G, Chiarelli F. Lack of association between antiphospholipid antibodies and migraine in children. Int J Clin Lab Res. 2000;30:109–111
  99. Cuadrado MJ, Khamashta MA, Hughes GR. Migraine and stroke in young women. QJM. 2000;93:317–318
  100. Tietjen GE, Day M, Norris L, Aurora S, Halvorsen A, Schultz LR, et al. Role of anticardiolipin antibodies in young persons with migraine and transient focal neurologic events: a prospective study. Neurology. 1998;50:1433–1440
  101. Sanna G, Bertolaccini ML, Cuadrado MJ, Khamashta MA, Hughes GR. Central nervous system involvement in the antiphospholipid (Hughes) syndrome. Rheumatology (Oxford). 2003;42:200–213
  102. Stojanovich L, Zandman-Goddard G, Pavlovich S, Sikanich N. Psychiatric manifestations in systemic lupus erythematosus. Autoimmun Rev. 2007;6:421–426
  103. Vargas-Alarcon G, Yamamoto-Furusho JK, Zuniga J, Canoso R, Granados J. HLA-DR7 in association with chlorpromazine-induced lupus anticoagulant (LA). J Autoimmun. 1997;10:579–583
  104. Sirois F. Steroid psychosis: a review. Gen Hosp Psychiatry. 2003;25:27–33
  105. Schwartz M, Rochas M, Weller B, Sheinkman A, Tal I, Golan D, et al. High association of anticardiolipin antibodies with psychosis. J Clin Psychiatry. 1998;59:20–23
  106. Janavs JL, Aminoff MJ. Dystonia and chorea in acquired systemic disorders. J Neurol Neurosurg Psychiatry. 1998;65:436–445
  107. Amital H, Langevitz P, Levy Y, Afek A, Goldberg I, Pras M, et al. Valvular deposition of antiphospholipid antibodies in the antiphospholipid syndrome: a clue to the origin of the disease. Clin Exp Rheumatol. 1999;17:99–102
  108. Klawans HL, Weiner WJ. The pharmacology of choreatic movement disorders. Prog Neurobiol. 1976;6:49–80
  109. Cervera R, Asherson RA, Font J, Tikly M, Pallares L, Chamorro A, et al. Chorea in the antiphospholipid syndrome (Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature). Medicine (Baltimore). 1997;76:203–212
  110. Wiechens B, Schroder JO, Potzsch B, Rochels R. Primary antiphospholipid antibody syndrome and retinal occlusive vasculopathy. Am J Ophthalmol. 1997;123:848–850
  111. Nahum A, Levy Y, Shoenfeld Y. Ocular manifestations in the antiphospholipid syndrome. Harefuah. 1999;136:50–53
  112. Gibbs AN, Moroney J, Foley-Nolan D, O'Connell PG. Neuromyelitis optica (Devic's syndrome) in systemic lupus erythematosus: a case report. Rheumatology (Oxford). 2002;41:470–471
  113. Giorgi D, Gabrieli CB, Bonomo L. The clinico-ophthalmological spectrum of antiphospholipid syndrome. Ocul Immunol Inflamm. 1998;6:269–273
  114. Reino S, Munoz-Rodriguez FJ, Cervera R, Espinosa G, Font J, Ingelmo M. Optic neuropathy in the “primary” antiphospholipid syndrome: report of a case and review of the literature. Clin Rheumatol. 1997;16:629–631
  115. Giorgi D, Balacco GC. Optic neuropathy in systemic lupus erythematosus and antiphospholipid syndrome (APS): clinical features, pathogenesis, review of the literature and proposed ophthalmological criteria for APS diagnosis. Clin Rheumatol. 1999;18:124–131
  116. Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GR. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? Analysis of 27 patients and review of the literature. Medicine (Baltimore). 2000;79:57–68
  117. Hughes GR. Migraine, memory loss, and “multiple sclerosis” (Neurological features of the antiphospholipid (Hughes') syndrome). Postgrad Med J. 2003;79:81–83
  118. Karussis D, Leker RR, Ashkenazi A, Abramsky O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity?. Ann Neurol. 1998;44:629–634
  119. Tourbah A, Clapin A, Gout O, Fontaine B, Liblau R, Batteux F, et al. Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study. Arch Neurol. 1998;55:517–521
  120. Bidot CJ, Horstman LL, Jy W, Jimenez JJ, Bidot C, Ahn YS, et al. Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study. BMC Neurol. 2007;7:36
  121. Berman M, Feldman S, Alter M, Zilber N, Kahana E. Acute transverse myelitis: incidence and etiologic considerations. Neurology. 1981;31:966–971
  122. Kovacs B, Lafferty TL, Brent LH, DeHoratius RJ. Transverse myelopathy in systemic lupus erythematosus: an analysis of 14 cases and review of the literature. Ann Rheum Dis. 2000;59:120–124
  123. Lavalle C, Pizarro S, Drenkard C, Sanchez-Guerrero J, Alarcon-Segovia D. Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol. 1990;17:34–37
  124. Ruiz-Arguelles GJ, Guzman-Ramos J, Flores-Flores J, Garay-Martinez J. Refractory hiccough heralding transverse myelitis in the primary antiphospholipid syndrome. Lupus. 1998;7:49–50
  125. Lavalle C, Pizarro S, Drenkard C, Sanchez-Guerrero J, Alarcon-Segovia D. Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol. 1990;17:34–37
  126. Shin SY, Lee JM. A case of multiple cranial nerve palsies as the initial ophthalmic presentation of antiphospholipid syndrome. Korean J Ophthalmol. 2006;20:76–78
  127. Falcini F, Taccetti G, Trapani S, Tafi L, Petralli S, Matucci-Cerinic M. Primary antiphospholipid syndrome: a report of two pediatric cases. J Rheumatol. 1991;18:1085–1087
  128. Kesler A, Ellis MH, Reshef T, Kott E, Gadoth N. Idiopathic intracranial hypertension and anticardiolipin antibodies. J Neurol Neurosurg Psychiatry. 2000;68:379–380
  129. Buller HR, Agnelli G, Hull RD, Hyers TM, Prins MH, Raskob GE. Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126:401S–428S
  130. Wardlaw JM, del ZG, Yamaguchi T. Thrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev. 2000;CD000213
  131. Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, et al. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291:576–584
  132. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med. 2001;345:1444–1451
  133. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 2006;295:1050–1057
  134. Roldan JF, Brey RL. Neurologic manifestations of the antiphospholipid syndrome. Curr Rheumatol Rep. 2007;9:109–115
  135. Alarcon-Segovia D, Boffa MC, Branch W, Cervera R, Gharavi A, Khamashta M, et al. Prophylaxis of the antiphospholipid syndrome: a consensus report. Lupus. 2003;12:499–503
  136. Roubey RA. New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. Arthritis Rheum. 2003;48:3004–3008
  137. Espinola RG, Pierangeli SS, Gharavi AE, Harris EN. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost. 2002;87:518–522
  138. Napoleone E, Di SA, Camera M, Tremoli E, Lorenzet R. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes. Circ Res. 2000;86:139–143
  139. Blank M, Anafi L, Zandman-Goddard G, Krause I, Goldman S, Shalev E, et al. The efficacy of specific IVIG anti-idiotypic antibodies in antiphospholipid syndrome (APS): trophoblast invasiveness and APS animal model. Int Immunol. 2007;19:857–865
  140. Hsiao GR, Wolf RE, Kimpel DL. Intravenous immunoglobulin to prevent recurrent thrombosis in the antiphospholipid syndrome. J Clin Rheumatol. 2001;7:336–339
  141. Chang P, Millar D, Tsang P, Lim K, Houlihan E, Stephenson M. Intravenous immunoglobulin in antiphospholipid syndrome and maternal floor infarction when standard treatment fails: a case report. Am J Perinatol. 2006;23:125–129
  142. Carp HJ, Sapir T, Shoenfeld Y. Intravenous immunoglobulin and recurrent pregnancy loss. Clin Rev Allergy Immunol. 2005;29:327–332
  143. Konova E. Intravenous immunoglobulin therapy in antiphospholipid syndrome. Clin Rev Allergy Immunol. 2005;29:229–236
  144. Arabshahi B, Thompson ED, Smergel EM, Goldsmith DP. Long-term treatment of antiphospholipid syndrome-associated cerebral arterial thromboses with intravenous immunoglobulin: a case report. Clin Rheumatol. 2007;26:251–253
  145. Shoenfeld Y, Katz U. IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients. Autoimmunity. 2005;38:123–137
  146. Roberts JR, Finger DR. Catastrophic antiphospholipid syndrome; a “CATASTROPHIC” case of systemic lupus erythematosus. Hawaii Med J. 2004;63:362–364
  147. McIntyre JA. The appearance and disappearance of antiphospholipid autoantibodies subsequent to oxidation–reduction reactions. Thromb Res. 2004;114:579–587
  148. Triolo G, Ferrante A, Accardo-Palumbo A, Ciccia F, Cadelo M, Castelli A, et al. IVIG in APS pregnancy. Lupus. 2004;13:731–735
  149. Horn HC, Grau K, Junker P. IVIG treatment for progressive stroke in the primary antiphospholipid antibody syndrome. Lupus. 2004;13:478–480
  150. Tincani A, Branch W, Levy RA, Piette JC, Carp H, Rai RS, et al. Treatment of pregnant patients with antiphospholipid syndrome. Lupus. 2003;12:524–529
  151. Sherer Y, Wu R, Kraus I, Peter JB, Shoenfeld Y. Antiphospholipid antibody levels in intravenous immunoglobulin (IVIg) preparations. Lupus. 2001;10:568–570
  152. Vinatier D, Dufour P, Cosson M, Houpeau JL. Antiphospholipid syndrome and recurrent miscarriages. Eur J Obstet Gynecol Reprod Biol. 2001;96:37–50
  153. Sherer Y, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy of antiphospholipid syndrome. Rheumatology (Oxford). 2000;39:421–426
  154. Asherson RA. The catastrophic antiphospholipid syndrome, 1998 (A review of the clinical features, possible pathogenesis and treatment). Lupus. 1998;7(Suppl 2):S55–S62
  155. Krause I, Blank M, Shoenfeld Y. Immunomodulation of experimental APS: lessons from murine models. Lupus. 1996;5:458–462
  156. Krause I, Blank M, Levi Y, Koike T, Barak V, Shoenfeld Y. Anti-idiotype immunomodulation of experimental anti-phospholipid syndrome via effect on Th1/Th2 expression. Clin Exp Immunol. 1999;117:190–197
  157. Krause I, Blank M, Shoenfeld Y. Treatment of systemic lupus erythematosus and antiphospholipid syndrome: from experimental models to patients' bedside. Int Arch Allergy Immunol. 1996;111:355–361
  158. Erre GL, Pardini S, Faedda R, Passiu G. Effect of rituximab on clinical and laboratory features of antiphospholipid syndrome: a case report and a review of literature. Lupus. 2008;17:50–55
  159. Pierangeli SS, Blank M, Liu X, Espinola R, Fridkin M, Ostertag MV, et al. A peptide that shares similarity with bacterial antigens reverses thrombogenic properties of antiphospholipid antibodies in vivo. J Autoimmun. 2004;22:217–225
  160. Wang MX, Kandiah DA, Ichikawa K, Khamashta M, Hughes G, Koike T, et al. Epitope specificity of monoclonal anti-beta 2-glycoprotein I antibodies derived from patients with the antiphospholipid syndrome. J Immunol. 1995;155:1629–1636
  161. Muscal E, Brey RL. Neurologic manifestations of the antiphospholipid syndrome: integrating molecular and clinical lessons. Curr Rheumatol Rep. 2008;10:67–73
  162. Hughes GR. Migraine, memory loss, and “multiple sclerosis” (Neurological features of the antiphospholipid (Hughes') syndrome). Postgrad Med J. 2003;79:81–83
  163. Tarr T, Lakos G, Bhattoa HP, Soltesz P, Shoenfeld Y, Szegedi G, et al. Clinical thrombotic manifestations in SLE patients with and without antiphospholipid antibodies: a 5-year follow-up. Clin Rev Allergy Immunol. 2007;32:131–137
  164. Saidi S, Mahjoub T, Almawi WY. Lupus anticoagulants and anti-phospholipid antibodies as risk factors for a first episode of ischemic stroke. J Thromb Haemost. 2009 Apr 24;[Epub ahead of print]
  165. Levine SR, Salowich-Palm L, Sawaya KL, Perry M, Spencer HJ, Winkler HJ, et al. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death (A prospective cohort study). Stroke. 1997;28:1660–1665
  166. Levine SR, Deegan MJ, Futrell N, Welch KM. Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology. 1990;40:1181–1189
  167. Nahum A, Levy Y, Shoenfeld Y. Ocular manifestations in the antiphospholipid syndrome. Harefuah. 1999;136:50–53
  168. Wiechens B, Schroder JO, Potzsch B, Rochels R. Primary antiphospholipid antibody syndrome and retinal occlusive vasculopathy. Am J Ophthalmol. 1997;123:848–850
  169. Gibbs AN, Moroney J, Foley-Nolan D, O'Connell PG. Neuromyelitis optica (Devic's syndrome) in systemic lupus erythematosus: a case report. Rheumatology (Oxford). 2002;41:470–471
  170. Giorgi D, Gabrieli CB, Bonomo L. The clinico-ophthalmological spectrum of antiphospholipid syndrome. Ocul Immunol Inflamm. 1998;6:269–273
  171. Reino S, Munoz-Rodriguez FJ, Cervera R, Espinosa G, Font J, Ingelmo M. Optic neuropathy in the “primary” antiphospholipid syndrome: report of a case and review of the literature. Clin Rheumatol. 1997;16:629–631
  172. Yehudai D, Shoenfeld Y, Toubi E. Looking into the eyes of patients with antiphospholipid syndrome. Clin Rev Allergy Immunol. 2007;32:192–197
  173. Hughes GR. Migraine, memory loss, and “multiple sclerosis” (Neurological features of the antiphospholipid (Hughes') syndrome). Postgrad Med J. 2003;79:81–83
  174. Levine SR, Joseph R, D'Andrea G, Welch KM. Migraine and the lupus anticoagulant (Case reports and review of the literature). Cephalalgia. 1987;7:93–99
  175. Hughes G. Hughes Syndrome: the antiphospholipid syndrome—a clinical overview. Clin Rev Allergy Immunol. 2007;32:3–12
  176. Shoenfeld Y, Lev S, Blatt I, Blank M, Font J, von LP, et al. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol. 2004;31:1344–1348
  177. Levine SR, Salowich-Palm L, Sawaya KL, Perry M, Spencer HJ, Winkler HJ, et al. IgG anticardiolipin antibody titer > 40 GPL and the risk of subsequent thrombo-occlusive events and death (A prospective cohort study). Stroke. 1997;28:1660–1665
  178. Sanna G, D'Cruz D, Cuadrado MJ. Cerebral manifestations in the antiphospholipid (Hughes) syndrome. Rheum Dis Clin North Am. 2006;32:465–490
  179. Eriksson K, Peltola J, Keranen T, Haapala AM, Koivikko M. High prevalence of antiphospholipid antibodies in children with epilepsy: a controlled study of 50 cases. Epilepsy Res. 2001;46:129–137
  180. Verrot D, San-Marco M, Dravet C, Genton P, Disdier P, Bolla G, et al. Prevalence and signification of antinuclear and anticardiolipin antibodies in patients with epilepsy. Am J Med. 1997;103:33–37
  181. Chapman J, Soloveichick L, Shavit S, Shoenfeld Y, Korczyn AD. Antiphospholipid antibodies bind ATP: a putative mechanism for the pathogenesis of neuronal dysfunction. Clin Dev Immunol. 2005;12:175–180
  182. Cervera R, Asherson RA, Font J, Tikly M, Pallares L, Chamorro A, et al. Chorea in the antiphospholipid syndrome (Clinical, radiologic, and immunologic characteristics of 50 patients from our clinics and the recent literature). Medicine (Baltimore). 1997;76:203–212
  183. Tektonidou MG, Varsou N, Kotoulas G, Antoniou A, Moutsopoulos HM. Cognitive deficits in patients with antiphospholipid syndrome: association with clinical, laboratory, and brain magnetic resonance imaging findings. Arch Intern Med. 2006;166:2278–2284
  184. Kao CH, Lan JL, Hsieh JF, Ho YJ, ChangLai SP, Lee JK, et al. Evaluation of regional cerebral blood flow with 99mTc-HMPAO in primary antiphospholipid antibody syndrome. J Nucl Med. 1999;40:1446–1450
  185. Shoenfeld Y, Twig G, Katz U, Sherer Y. Autoantibody explosion in antiphospholipid syndrome. J Autoimmun. 2008;30:74–83
  186. Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies (A mouse model). J Clin Invest. 1997;100:613–619
  187. Ziporen L, Polak-Charcon S, Korczyn DA, Goldberg I, Afek A, Kopolovic J, et al. Neurological dysfunction associated with antiphospholipid syndrome: histopathological brain findings of thrombotic changes in a mouse model. Clin Dev Immunol. 2004;11:67–75
  188. Mosek A, Yust I, Treves TA, Vardinon N, Korczyn AD, Chapman J. Dementia and antiphospholipid antibodies. Dement Geriatr Cogn Disord. 2000;11:36–38
  189. Juby A, Davis P, Genge T, McElhaney J. Anticardiolipin antibodies in two elderly subpopulations. Lupus. 1995;4:482–485
  190. Cervera R, Piette JC, Font J, Khamashta MA, Shoenfeld Y, Camps MT, et al. Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients. Arthritis Rheum. 2002;46:1019–1027
  191. Menon S, Jameson-Shortall E, Newman SP, Hall-Craggs MR, Chinn R, Isenberg DA. A longitudinal study of anticardiolipin antibody levels and cognitive functioning in systemic lupus erythematosus. Arthritis Rheum. 1999;42:735–741
  192. Katzav A, Faust-Socher A, Kvapil F, Michaelson DM, Blank M, Pick CG, et al. Antiphospholipid syndrome induction exacerbates a transgenic Alzheimer disease model on a female background. Neurobiol Aging. 2009 Mar 10;[Epub ahead of print]
  193. Sherer Y, Gorstein A, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum. 2004;34:501–537
  194. Ziporen L, Shoenfeld Y, Levy Y, Korczyn AD. Neurological dysfunction and hyperactive behavior associated with antiphospholipid antibodies (A mouse model). J Clin Invest. 1997;100:613–619
  195. Colasanti T, Delunardo F, Margutti P, Vacirca D, Piro E, Siracusano A, et al. Autoantibodies involved in neuropsychiatric manifestations associated with Systemic Lupus Erythematosus. J Neuroimmunol. 2009 Jun 3;[Epub ahead of print]
  196. Schwartz M, Rochas M, Weller B, Sheinkman A, Tal I, Golan D, et al. High association of anticardiolipin antibodies with psychosis. J Clin Psychiatry. 1998;59:20–23
  197. Cuadrado MJ, Khamashta MA, Ballesteros A, Godfrey T, Simon MJ, Hughes GR. Can neurologic manifestations of Hughes (antiphospholipid) syndrome be distinguished from multiple sclerosis? (Analysis of 27 patients and review of the literature). Medicine (Baltimore). 2000;79:57–68
  198. Karussis D, Leker RR, Ashkenazi A, Abramsky O. A subgroup of multiple sclerosis patients with anticardiolipin antibodies and unusual clinical manifestations: do they represent a new nosological entity?. Ann Neurol. 1998;44:629–634
  199. Tourbah A, Clapin A, Gout O, Fontaine B, Liblau R, Batteux F, et al. Systemic autoimmune features and multiple sclerosis: a 5-year follow-up study. Arch Neurol. 1998;55:517–521
  200. Lavalle C, Pizarro S, Drenkard C, Sanchez-Guerrero J, Alarcon-Segovia D. Transverse myelitis: a manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies. J Rheumatol. 1990;17:34–37
  201. Mortifee PR, Bebb RA, Stein H. Communicating hydrocephalus in systemic lupus erythematosus with antiphospholipid antibody syndrome. J Rheumatol. 1992;19:1299–1302
  202. Shin SY, Lee JM. A case of multiple cranial nerve palsies as the initial ophthalmic presentation of antiphospholipid syndrome. Korean J Ophthalmol. 2006;20:76–78
  203. Falcini F, Taccetti G, Trapani S, Tafi L, Petralli S, Matucci-Cerinic M. Primary antiphospholipid syndrome: a report of two pediatric cases. J Rheumatol. 1991;18:1085–1087
  204. Miesbach W, Gilzinger A, Gokpinar B, Claus D, Scharrer I. Prevalence of antiphospholipid antibodies in patients with neurological symptoms. Clin Neurol Neurosurg. 2006;108:135–142

PII: S0049-0172(09)00055-9

doi: 10.1016/j.semarthrit.2009.05.001

Seminars in Arthritis and Rheumatism
Volume 40, Issue 2 , Pages 97-108 , October 2010

Article Tools